ALNY beat EPS expectations by 34.98%
Jul 31, 2025, 10:33 PM
0.00%
What does ALNY do
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Alnylam Pharmaceuticals (ALNY) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Alnylam Pharmaceuticals's actual EPS was -$0.51, beating the estimate of -$0.78 per share, resulting in a 34.98% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.